Present invention relates to an allergy-inhibiting sea grape extract, its preparation method and thereof. The preparation method includes following steps: the sea grape is blended in distilled water in the weight ratio of 1:120, mix thoroughly, stir at 20100 C. for 30120 minutes. The fluid obtained after the first filtration is the sea grape extract. The sea grape extract can be subjected to the second filtration by using EW, PW and DK membranes and freeze-dried to give a refined sea grape extract. The invention exhibits superior allergy-inhibiting effect; moreover, the prepared extract does not cause allergy and can be used in cosmetics and food.

Present invention relates to an allergy-inhibiting sea grape extract, its preparation method and thereof. The preparation method includes following steps: the sea grape is blended in distilled water in the weight ratio of 1:120, mix thoroughly, stir at 20100 C. for 30120 minutes. The fluid obtained after the first filtration is the sea grape extract. The sea grape extract can be subjected to the second filtration by using EW, PW and DK membranes and freeze-dried to give a refined sea grape extract. The invention exhibits superior allergy-inhibiting effect; moreover, the prepared extract does not cause allergy and can be used in cosmetics and food.

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori. Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori. Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.

The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient, and the neoagarooligosaccharide according to the present invention has an excellent effect in terms of immune enhancement by effectively suppressing inflammation, and also exhibits a good effect in preventing sepsis, and therefore can be effectively used in pharmaceuticals and functional foods for prevention or treatment of sepsis or septic shock and immune enhancement.

The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient, and the neoagarooligosaccharide according to the present invention has an excellent effect in terms of immune enhancement by effectively suppressing inflammation, and also exhibits a good effect in preventing sepsis, and therefore can be effectively used in pharmaceuticals and functional foods for prevention or treatment of sepsis or septic shock and immune enhancement.

The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).

The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).

The present invention relates to the use of non-digestible oligosaccharides for the direct attenuation of nasal epithelial inflammation, in particular for non-allergic rhinitis, in particular for use in infants.

The present invention relates to the use of non-digestible oligosaccharides for the direct attenuation of nasal epithelial inflammation, in particular for non-allergic rhinitis, in particular for use in infants.